skip to content


BTG receives FDA clearance for EKOS

27 February 2017 13:10

BTG has received 510(k) clearance from the US Food and Drug Administration in respect of its EKOS Control Unit 4.0, used to dissolve blood clots and restore blood flow in patients with pulmonary embolism (PE), deep vein thrombosis (DVT), and peripheral arterial occlusions (PAO).

"Currently the only device cleared for the treatment of pulmonary embolism, EKOS has been in a leadership position in the PE treatment market since the beginning," said BTG Vice President and General Manager Matt Stupfel.

"Now, BTG is further solidifying our leadership positon with the EKOS Control Unit 4.0. This new platform will allow for further device innovation to simplify treatment for clinicians and improve outcomes for patients."

At 1:10pm: (LON:BTG) BTG PLC share price was +7.5p at 573.5p

Story provided by

Related Company: BTG

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.